Endocrine therapy or hormone therapy (HT) is a common and reportedly effective treatment for ER+ and PR+ breast cancers; however, it is also associated with certain varying risks, depending on the drug and mechanism of action. The gene discussed is ESR1; the disease is breast carcinoma.